Document is current
Any future updates will be listed below
-
Authors
Bellerba, Federica
Chatziioannou, Anastasia Chrysovalantou
Jasbi, Paniz
Robinot, Nivonirina
Keski-Rahkonen, Pekka
Trolat, Amarine
Vozar, Béatrice
Hartman, Sheri J.
Scalbert, Augustin
Bonanni, Bernardo
Johansson, Harriet https://orcid.org/0000-0002-4131-2030
Sears, Dorothy D.
Gandini, Sara
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct01302379 at ClinicalTrials.govDocuments that mention this clinical trial
Metabolomic profiles of metformin in breast cancer survivors: a pooled analysis of plasmas from two randomized placebo-controlled trials
https://doi.org/10.1186/s12967-022-03809-6
-
Funding
Funding for this research was provided by:
Institut National du Cancer, France (INCa Nr 2015-034)
National Institutes of Health (CA155435)
Italian Ministry of Health (RRC-2014-2354553)
- License Information
-
More Information
Article History
Received: 7 September 2022
Accepted: 5 December 2022
First Online: 29 December 2022
Declarations
:
: The Reach for Health Study (RFH) was approved by the Human Research Protections Program at UC San Diego, and participants signed informed consent forms (ClinicalTrials.gov identifier: NCT01302379). Details regarding the study design, recruitment strategies, interventions and primary outcomes have been previously published [,]. The MetBreCS trial, A randomized placebo-controlled phase II study with metformin in metabolic-unbalanced breast cancer survivors at higher risk for recurrence, was conducted at the European Institute of Oncology, Milan, Italy (EudraCT Protocol #: 2015-001001-14). The trial was approved by the local IRB and participants signed informed consent.
: The authors declare no potential financial and non-financial competing interests.
